UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Trastuzumab: updated mechanisms of action and resistance in breast cancer

Frontiers in oncology, 2012, Vol.2, p.62-62

2012

Link zum Volltext

Verfügbarkeit prüfen

Activating HER3 mutations in breast cancer

Oncotarget, 2018-06, Vol.9 (45), p.27773-27788

2018

Link zum Volltext

Verfügbarkeit prüfen

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

Oncotarget, 2020-01, Vol.11 (1), p.31-45

2020

Link zum Volltext

Verfügbarkeit prüfen

HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

Genes & diseases, 2024-06, p.101354, Article 101354

2024

Link zum Volltext

Verfügbarkeit prüfen

New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer

MedComm - Oncology, 2022-09, Vol.1 (2), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells

Cell cycle (Georgetown, Tex.), 2015-02, Vol.14 (4), p.648-655

2015

Link zum Volltext

Verfügbarkeit prüfen

Understanding the biology of HER3 receptor as a therapeutic target in human cancer

Acta pharmaceutica Sinica. B, 2018-07, Vol.8 (4), p.503-510

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparative evaluation of [sup.111]In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Oncology reports, 2015-08, p.1042

2015

Link zum Volltext

Verfügbarkeit prüfen

HER3 receptor and its role in the therapeutic management of metastatic breast cancer

Journal of translational medicine, 2024-07, Vol.22 (1), p.665-15, Article 665

2024

Link zum Volltext

Verfügbarkeit prüfen

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68 Ga-Labeled Tracers

International journal of molecular sciences, 2019, Vol.20 (5)

2019

Link zum Volltext

Verfügbarkeit prüfen

Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling

Breast cancer research : BCR, 2004-03, Vol.6 (3), p.R246-R246, Article R246

2004

Link zum Volltext

Verfügbarkeit prüfen

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring

Future oncology (London, England), 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers

Frontiers in molecular biosciences, 2022-02, Vol.9, p.847835-847835

2022

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Frontiers in immunology, 2024, Vol.15, p.1376045-1376045

2024

Link zum Volltext

Verfügbarkeit prüfen

HER3 over-expression and overall survival in gastrointestinal cancers

Oncotarget, 2015-12, Vol.6 (40), p.42868-42878

2015

Link zum Volltext

Verfügbarkeit prüfen

The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer

BMC cancer, 2016-11, Vol.16 (1)

2016

Link zum Volltext

Verfügbarkeit prüfen

HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma

Oncotarget, 2023-05, Vol.14 (1), p.439-443

2023

Link zum Volltext

Verfügbarkeit prüfen

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells

Biochemistry and biophysics reports, 2022-09, Vol.31, p.101326-101326, Article 101326

2022

Link zum Volltext

Verfügbarkeit prüfen

Cover Feature: Synthetic Modular Antibody Construction by Using the SpyTag/SpyCatcher Protein‐Ligase System (ChemBioChem 22/2017)

Chembiochem : a European journal of chemical biology, 2017-11, Vol.18 (22), p.2191-2191

2017

Link zum Volltext

Verfügbarkeit prüfen

Oncogenic Signaling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities

Dricu, Anica

2023

Link zum Volltext

Verfügbarkeit prüfen

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination

The Journal of pathology, 2012-06, Vol.227 (2), p.234-244

2012

Link zum Volltext

Verfügbarkeit prüfen

HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors

Chinese Medical Journal - Pulmonary and Critical Care Medicine, 2023-03, Vol.1 (1), p.11-17

2023

Link zum Volltext

Verfügbarkeit prüfen

HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers

Cancers, 2021-09, Vol.13 (19), p.4791

2021

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

Frontiers in oncology, 2016-10, Vol.6

2016

Link zum Volltext

Verfügbarkeit prüfen

Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines

Asian Pacific journal of cancer prevention : APJCP, 2020-02, Vol.21 (2), p.439-447

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 58

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Trastuzumab: updated mechanisms of action and resistance in breast cancer

Activating HER3 mutations in breast cancer

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells

Understanding the biology of HER3 receptor as a therapeutic target in human cancer

Comparative evaluation of [sup.111]In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors

HER3 receptor and its role in the therapeutic management of metastatic breast cancer

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68 Ga-Labeled Tracers

Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring

Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

HER3 over-expression and overall survival in gastrointestinal cancers

The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer

HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells

Cover Feature: Synthetic Modular Antibody Construction by Using the SpyTag/SpyCatcher Protein‐Ligase System (ChemBioChem 22/2017)

Oncogenic Signaling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination

HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors

HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers

Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines

Aktive Filter

Suchergebnisse filtern